[go: up one dir, main page]

MA48637A - Polythérapies pour le traitement du cancer - Google Patents

Polythérapies pour le traitement du cancer

Info

Publication number
MA48637A
MA48637A MA048637A MA48637A MA48637A MA 48637 A MA48637 A MA 48637A MA 048637 A MA048637 A MA 048637A MA 48637 A MA48637 A MA 48637A MA 48637 A MA48637 A MA 48637A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancer
treatment
Prior art date
Application number
MA048637A
Other languages
English (en)
Inventor
Dmitri Bobilev
Bruce Dezube
Andrew R Ferguson
Peng Sun
Original Assignee
Merck Sharp & Dohme
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Tesaro Inc filed Critical Merck Sharp & Dohme
Publication of MA48637A publication Critical patent/MA48637A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K1/00—Housing animals; Equipment therefor
    • A01K1/01—Removal of dung or urine ; Removal of manure from stables
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/20—Analysis of motion
    • G06T7/215—Motion-based segmentation
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01R—ELECTRICALLY-CONDUCTIVE CONNECTIONS; STRUCTURAL ASSOCIATIONS OF A PLURALITY OF MUTUALLY-INSULATED ELECTRICAL CONNECTING ELEMENTS; COUPLING DEVICES; CURRENT COLLECTORS
    • H01R13/00—Details of coupling devices of the kinds covered by groups H01R12/70 or H01R24/00 - H01R33/00
    • H01R13/46—Bases; Cases
    • H01R13/516—Means for holding or embracing insulating body, e.g. casing, hoods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA048637A 2017-05-09 2018-05-09 Polythérapies pour le traitement du cancer MA48637A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762503879P 2017-05-09 2017-05-09
US201762508359P 2017-05-18 2017-05-18
US201762556255P 2017-09-08 2017-09-08
US201862634789P 2018-02-23 2018-02-23
US201862646332P 2018-03-21 2018-03-21
US201862648327P 2018-03-26 2018-03-26

Publications (1)

Publication Number Publication Date
MA48637A true MA48637A (fr) 2021-03-17

Family

ID=64105496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048637A MA48637A (fr) 2017-05-09 2018-05-09 Polythérapies pour le traitement du cancer

Country Status (14)

Country Link
US (2) US12156872B2 (fr)
EP (1) EP3621592A4 (fr)
JP (2) JP2020519621A (fr)
KR (1) KR20200018436A (fr)
CN (1) CN110831580A (fr)
AU (3) AU2018264992A1 (fr)
BR (1) BR112019023591A2 (fr)
CA (1) CA3063201A1 (fr)
IL (1) IL270511B2 (fr)
MA (1) MA48637A (fr)
MX (1) MX2019013373A (fr)
TW (2) TWI879716B (fr)
WO (1) WO2018208968A1 (fr)
ZA (1) ZA201907395B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
CN118271233A (zh) 2017-04-24 2024-07-02 特沙诺有限公司 尼拉帕利的制造方法
WO2018208968A1 (fr) 2017-05-09 2018-11-15 Tesaro, Inc. Polythérapies pour le traitement du cancer
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
BR112020006845A2 (pt) 2017-10-06 2020-10-06 Tesaro, Inc. terapias combinadas e usos das mesmas
TW201938165A (zh) * 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン（シャンハイ） ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20250114450A1 (en) * 2021-03-12 2025-04-10 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
US20240366584A1 (en) 2021-06-21 2024-11-07 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
JP2025508399A (ja) 2022-02-15 2025-03-26 テサロ， インコーポレイテッド 脳がんの処置のためのニラパリブの使用
WO2025128263A1 (fr) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anticorps monoclonal anti-pd-1 et ses procédés de préparation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333363C (fr) 1988-01-19 1994-12-06 Judah Folkman Inhibiteur de l'angiogenese contenant de la fumagilline
CA1329771C (fr) 1988-09-01 1994-05-24 Shoji Kishimoto Agent inhibiteur de l'angiogenese
EP2243493A1 (fr) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Composition immunostimulante
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
CA2674436C (fr) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Indazoles a substitution amide utilises comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
AU2008321128A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101918003A (zh) 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
EP2237684A2 (fr) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonistes pour des systèmes peptidiques antimicrobiens
WO2009087381A1 (fr) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Sels pharmaceutiquement acceptables de 2-{4-[(35)-pipéridin-3-yl]phényl)-2h-indazole-7-carboxamide
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
TW201032796A (en) 2009-02-04 2010-09-16 Bipar Sciences Inc Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
WO2011153383A1 (fr) * 2010-06-04 2011-12-08 Bipar Science, Inc. Procédés de traitement d'un cancer des ovaires récurrent et résistant au platine avec du 4-iodo-3-nitrobenzamide en combinaison avec un antimétabolite et un composé de platine.
DK3327148T3 (da) 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
AU2011293635B2 (en) 2010-08-24 2015-11-26 Children's Medical Center Corporation Methods for predicting anti-cancer response
CA2742342A1 (fr) 2011-02-12 2012-08-12 Baylor Research Institute Le statut a l'egard de l'expression de msh3 determine le degre de reponse des cellules cancereuses a un traitement chimiotherapeutique faisant intervenir des inhibiteurs de la parp et des medicaments a base de platine
EP2785375B1 (fr) 2011-11-28 2020-07-22 Merck Patent GmbH Anticorps anti-pd-l1 et leur utilisation
WO2013182645A1 (fr) 2012-06-07 2013-12-12 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
ES2672328T3 (es) 2012-12-07 2018-06-13 Merck Sharp & Dohme Corp. Proceso de transaminación biocatalítica
US9850542B2 (en) 2013-03-04 2017-12-26 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (HR) deficient cancer
AR095363A1 (es) 2013-03-15 2015-10-14 Genentech Inc Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
EP4023765A1 (fr) 2013-12-09 2022-07-06 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
JP6663350B2 (ja) 2014-01-16 2020-03-11 クロヴィス・オンコロジー，インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
WO2015116868A2 (fr) 2014-01-29 2015-08-06 Caris Mpi, Inc. Profilage moléculaire de modulateurs immunitaires
BR112016017256A2 (pt) 2014-02-04 2017-10-17 Merck Sharp & Dohme combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
CA2943834A1 (fr) 2014-03-31 2015-10-08 Genentech, Inc. Therapie combinatoires comprenant des agents anti-angiogenese et des agonistes se liant a ox40
EP3148336B1 (fr) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. L'éribuline et des inhibiteurs de la poly(adp-ribose) polymérase (parp) en tant que que polythérapie pour le traitement du cancer
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
EP3303397A1 (fr) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Méthodes destinées à traiter le cancer à l'aide d'anticorps anti-ox40 et d'antagonistes se liant à l'axe pd-1
CN114796501A (zh) * 2015-06-25 2022-07-29 免疫医疗公司 抗体与治疗剂的组合治疗癌症的方法
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
EP3368041A4 (fr) 2015-10-26 2019-07-17 Medivation Technologies LLC Traitement du cancer du poumon à petites cellules avec un inhibiteur de parp
US20210322415A1 (en) 2016-02-15 2021-10-21 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
CN110087730B (zh) 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CA3041684C (fr) 2016-11-01 2023-09-26 Anaptysbio, Inc. Anticorps diriges contre la mort programmee 1 (pd -1)
MA50677A (fr) 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TWI793094B (zh) * 2017-01-09 2023-02-21 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
PL3565844T3 (pl) 2017-01-09 2023-06-12 Tesaro Inc. Sposoby leczenia nowotworów złośliwych przeciwciałami anty-pd-1
KR20190130625A (ko) 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
CN118271233A (zh) 2017-04-24 2024-07-02 特沙诺有限公司 尼拉帕利的制造方法
EP3615572A1 (fr) * 2017-04-27 2020-03-04 Tesaro Inc. Agents anticorps dirigés contre la protéine codée par le gène d'activation des lymphocytes 3 (lag-3) et utilisations associées
WO2018208968A1 (fr) 2017-05-09 2018-11-15 Tesaro, Inc. Polythérapies pour le traitement du cancer
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
JP2020536066A (ja) 2017-09-30 2020-12-10 テサロ， インコーポレイテッド 癌を治療するための併用療法
BR112020006845A2 (pt) 2017-10-06 2020-10-06 Tesaro, Inc. terapias combinadas e usos das mesmas
US20210106574A1 (en) 2017-12-27 2021-04-15 Tesaro, Inc. Methods of Treating Cancer
CN111918667A (zh) 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
EA201992594A1 (ru) 2018-03-26 2020-03-20 Тесаро, Инк. Комбинированные терапии для лечения рака
US11970530B2 (en) 2020-08-13 2024-04-30 Astrazeneca Ab Methods of treating homologous recombination deficient cancer

Also Published As

Publication number Publication date
US12156872B2 (en) 2024-12-03
IL270511B2 (en) 2024-12-01
TW201906632A (zh) 2019-02-16
EP3621592A4 (fr) 2021-03-17
AU2018264992A1 (en) 2019-12-05
CA3063201A1 (fr) 2018-11-15
AU2021218080A1 (en) 2021-09-09
AU2021218080B2 (en) 2023-12-14
AU2023274126A1 (en) 2024-02-01
WO2018208968A1 (fr) 2018-11-15
US20240226082A1 (en) 2024-07-11
CN110831580A (zh) 2020-02-21
MX2019013373A (es) 2020-08-03
IL270511B1 (en) 2024-08-01
IL270511A (en) 2019-12-31
JP2020519621A (ja) 2020-07-02
EP3621592A1 (fr) 2020-03-18
KR20200018436A (ko) 2020-02-19
US20200289493A1 (en) 2020-09-17
ZA201907395B (en) 2025-01-29
JP2023093603A (ja) 2023-07-04
TWI879716B (zh) 2025-04-11
BR112019023591A2 (pt) 2020-05-26
TW202444417A (zh) 2024-11-16
JP7717749B2 (ja) 2025-08-04

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3368559A4 (fr) Compositions et méthodes pour le du traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome